ElectroCore. has filed a patent for a method to modify microglia in humans by applying an electric current to the vagus nerve through the skin. The current alters microglia from a pro-inflammatory to a non-inflammatory state, potentially improving brain health and cognitive functions. GlobalData’s report on ElectroCore gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights ElectroCore Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ElectroCore, Cardiac stimulation implants was a key innovation area identified from patents. ElectroCore's grant share as of January 2024 was 65%. Grant share is based on the ratio of number of grants to total number of patents.

Modifying microglia in human by applying electric current

Source: United States Patent and Trademark Office (USPTO). Credit: ElectroCore Inc

A recently filed patent (Publication Number: US20230405306A1) outlines a method for modifying microglia in humans by applying an electric current through the outer skin surface to the vagus nerve. The current, consisting of electrical impulses with a frequency of 2.5 kHz to 10 kHz, is designed to shift microglia in the central nervous system from a pro-inflammatory to a non-inflammatory state. This method aims to reduce the expression of proinflammatory cytokines like TNF-a while increasing the expression of anti-inflammatory cytokines and brain-derived neurotrophic factor (BDNF). By stimulating the vagus nerve, the electrical impulse can also impact serotonin reuptake transporters, potentially influencing brain function and neurostructural development.

Furthermore, the patent describes a method for enhancing neurostructural development in individuals, particularly children under 18 years old, by applying an electrical impulse to the vagus nerve according to a specific stimulation protocol. This protocol involves administering doses multiple times a day for an extended period, aiming to increase the effectiveness of the neural network, connectivity of neurons, and neuronal plasticity in the brain. The method also suggests potential benefits such as increased intelligence, emotional stability, memory retention, alertness, and speed of learning. With doses separated by short intervals and administered consistently over at least 90 days or even a year, this method could have significant implications for cognitive development and overall brain function in young individuals.

To know more about GlobalData’s detailed insights on ElectroCore, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies